The size of the Pancreatic Cancer Therapeutics Market in Europe was worth USD 0.63 billion in 2020 and estimated to be growing at a CAGR of 6.98 %, to reach USD 0.88 billion by 2025.
Pancreatic cancer is caused by the uncontrolled growth of cells in the pancreas. This abnormal, unrestrained growth of cells results in the formation of lumps of tissue, widely referred to as tumors. The occurrence and mortality rate of pancreatic cancer is more in men than in women. Pancreatic cancer is currently the 4th leading cause of death by cancer in Europe. And it is expected to become 2nd by 2020.
Pancreatic cancer starts when cells in the pancreas start to grow incessantly eventually resulting in symptoms like abdominal pain, weight loss, diarrhea, and jaundice. The developed tumor hinders the normal functioning of pancreas. The biggest risk factor which leads to pancreatic cancer is smoking. Apart from lifestyle dependent factors like alcohol consumption, obesity and smoking, a personal or family history of pancreatitis or old age may result in a person being affected by pancreatic cancer. Pancreatic cancer patients lose 98% of their healthy life expectancy at the point of diagnosis itself.
Pancreatic cancer mortality rates are increasing in many countries across the continent, and it is estimated it will cause 91,500 deaths next year. Clearly, this is also the most challenging aspect that this market needs to address. Given the insuppressible nature of pancreatic cancer, treatments often return insufficient results. This challenge is yet another barrier to the growth of this market. Technologies are yet to develop fully for the timely diagnosis of this cancer type, which results in the diagnosis of majority of pancreatic cancer patients at an advanced stage of the disease. This explains the high mortality rates associated with pancreatic cancer. Estimates show that only a small percentage, that is about 12% to 15% of the patients is diagnosed early enough to be treated with surgical procedures, drugs, and chemotherapy.
This research report on the European Pancreatic Cancer Therapeutics Market is segmented & sub-segmented into the following categories:
By Treatment Type:
By Cancer Type:
By End User:
By Country:
Notable companies leading the European pancreatic cancer therapeutics market profiled in this report are Eli Lilly, Amgen, Inc., Celgene Corp., F. Hoffmann-La Roche, Clovis Oncology Inc., Pfizer, Novartis AG, Threshold Pharmaceuticals Inc., Aduro BioTech Inc., Infinity Pharmaceuticals Inc. and NewLink Genetics Corp.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Type of Treatment
5.1.1 Introduction
5.1.2 Surgery
5.1.3 Chemotherapy
5.1.4 Radiation Therapy
5.1.5 Others
5.1.6 Y-o-Y Growth Analysis, By Type of Treatment
5.1.7 Market Attractiveness Analysis, By Type of Treatment
5.1.8 Market Share Analysis, By Type of Treatment
5.2 Type
5.2.1 Introduction
5.2.2 Exocrine Pancreas Cancer
5.2.3 Endocrine Pancreas Cancer
5.2.4 Y-o-Y Growth Analysis, By Type
5.2.5 Market Attractiveness Analysis, By Type
5.2.6 Market Share Analysis, By Type
5.3 End-users
5.3.1 Introduction
5.3.2 Hospitals
5.3.3 Clinics
5.3.4 Research Institutes
5.3.5 Others
5.3.6 Y-o-Y Growth Analysis, By End-users
5.3.7 Market Attractiveness Analysis, By End-users
5.3.8 Market Share Analysis, By End-users
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Type of Treatment
6.1.3.3 By Type
6.1.3.4 By End-users
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Type of Treatment
6.1.4.3 By Type
6.1.4.4 By End-users
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Type of Treatment
6.1.5.3 By Type
6.1.5.4 By End-users
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Eli Lilly
8.1.1 Overview
8.1.2 Type of Product
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Amgen, Inc.
8.3 Celgene Corp.
8.4 F. Hoffmann-La Roche
8.5 Clovis Oncology Inc.
8.6 Pfizer
8.7 Novartis AG
8.8 Threshold Pharmaceuticals Inc.
8.9 Aduro BioTech Inc.
8.10 Infinity Pharmaceuticals Inc.
8.11 NewLink Genetics Corp.
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Request Sample Market Brochure of the report to get access to the List of Tables and List of Figures of the report
Related Reports
